3|0|Public
5000|$|Adefovir, {{also known}} as ADV or bis-POM PMPA, has trade names <b>Preveon</b> and Hepsera. It not {{approved}} by the FDA for treatment of HIV due to toxicity issues, but a lower dose is approved {{for the treatment of}} hepatitis B.|$|E
50|$|Adefovir is a {{prescription}} medicine {{used to treat}} (chronic) infections with hepatitis B virus. A prodrug form of adefovir was previously called bis-POM PMEA, with trade names <b>Preveon</b> and Hepsera. It is an orally administered nucleotide analog reverse transcriptase inhibitor (ntRTI). It can be formulated as the pivoxil prodrug adefovir dipivoxil.|$|E
50|$|Adefovir {{was invented}} in the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic by Antonín Holý, and the drug was {{developed}} by Gilead Sciences for HIV with the brand name <b>Preveon.</b> However, in November 1999, an expert panel advised the U.S. Food and Drug Administration (FDA) not to approve the drug due to concerns about the severity and frequency of kidney toxicity when dosed at 60 or 120 mg. The FDA followed that advice, refusing to approve adefovir {{as a treatment for}} HIV.|$|E

